Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
The American Society of Clinical Oncology 2011 Conference takes place on June 3-7 and The Doctor’s Channel will be providing daily highlights coverage. Check back daily for highlights…
NEW YORK (Reuters Health) – Patients with advanced cervical carcinoma have better progression-free survival when gemcitabine is added to concurrent cisplatin chemoradiotherapy and included in adjuvant therapy, an…
NEW YORK (Reuters Health) – Men who receive radiation treatment for prostate cancer are at greater risk of hip fracture, a new study in the March 16 issue…
NEW YORK (Reuters Health) – Drug-related pneumonitis is a class-effect toxicity of mammalian target of rapamycin (mTOR) inhibitors and temsirolimus is no exception, new research confirms. In the…
Nanette B. Silverberg, MD, director of Pediatric and Adolescent Dermatology St. Luke’s – Roosevelt Hospital Center, New York, discusses melanoma and its increasing incidence. This has occurred in…
NEW YORK (Reuters Health) – The incidence of esophageal adenocarcinoma in patients with nondysplastic Barrett’s esophagus is lower than previously reported, so less rigorous surveillance may be possible,…
NEW YORK (Reuters Health) – For patients with acute malignant obstruction of the left-sided colon, placement of colonic stents as a bridge to elective surgery offers no advantage…
David B. Solit, MD, Elizabeth and Felix Rohatyn Chair for Junior Faculty, Memorial Sloan-Kettering Cancer Center, discusses B-Raf, an intracellular signaling protein.B-Raf is commonly mutated in cancer, and…
NEW YORK (Reuters Health) – A negative sentinel lymph node (SLN) biopsy in patients with melanoma is associated with a low likelihood of disease recurrence involving the lymph…
NEW YORK (Reuters Health) – Combined with ondansetron and dexamethasone, a single intravenous dose of fosaprepitant is as effective as a standard 3-day oral course of aprepitant for…
